MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma

Teresa L. Tinder, Durai B. Subramani, Gargi D. Basu, Judy M. Bradley, Jorge Schettini, Arefayene Million, Todd Skaar, Pinku Mukherjee

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

MUC1, a membrane tethered mucin glycoprotein, is overexpressed and aberrantly glycosylated in >80% of human ductal pancreatic adenocarcinoma. However, the role of MUC1 in pancreatic cancer has been elusive, partly due to the lack of an appropriate model. We report the characterization of a novel mouse model that expresses human MUC1 as a self molecule (PDA.MUC1 mice). Pancreatic tumors arise in an appropriate MUC1-tolerant background within an immune-competent host. Significant enhancement in the development of pancreatic intraepithelial preneoplastic lesions and progression to adenocarcinoma is observed in PDA.MUC1 mice, possibly due to increased proliferation. Tumors from PDA.MUC1 mice express higher levels of cyclooxygenase-2 and IDO compared with PDA mice lacking MUC1, especially during early stages of tumor development. The increased proinflammatory milieu correlates with an increased percentage of regulatory T cells and myeloid suppressor cells in the pancreatic tumor and tumor draining lymph nodes. Data shows that during pancreatic cancer progression, MUC1-mediated mechanisms enhance the onset and progression of the disease, which in turn regulate the immune responses. Thus, the mouse model is ideally suited for testing novel chemopreventive and therapeutic strategies against pancreatic cancer.

Original languageEnglish
Pages (from-to)3116-3125
Number of pages10
JournalJournal of Immunology
Volume181
Issue number5
StatePublished - Sep 1 2008

Fingerprint

Immunosuppression
Adenocarcinoma
Pancreatic Neoplasms
Neoplasms
Mucins
Regulatory T-Lymphocytes
Myeloid Cells
Cyclooxygenase 2
Disease Progression
Glycoproteins
Lymph Nodes
Membranes

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Tinder, T. L., Subramani, D. B., Basu, G. D., Bradley, J. M., Schettini, J., Million, A., ... Mukherjee, P. (2008). MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. Journal of Immunology, 181(5), 3116-3125.

MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. / Tinder, Teresa L.; Subramani, Durai B.; Basu, Gargi D.; Bradley, Judy M.; Schettini, Jorge; Million, Arefayene; Skaar, Todd; Mukherjee, Pinku.

In: Journal of Immunology, Vol. 181, No. 5, 01.09.2008, p. 3116-3125.

Research output: Contribution to journalArticle

Tinder, TL, Subramani, DB, Basu, GD, Bradley, JM, Schettini, J, Million, A, Skaar, T & Mukherjee, P 2008, 'MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma', Journal of Immunology, vol. 181, no. 5, pp. 3116-3125.
Tinder TL, Subramani DB, Basu GD, Bradley JM, Schettini J, Million A et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. Journal of Immunology. 2008 Sep 1;181(5):3116-3125.
Tinder, Teresa L. ; Subramani, Durai B. ; Basu, Gargi D. ; Bradley, Judy M. ; Schettini, Jorge ; Million, Arefayene ; Skaar, Todd ; Mukherjee, Pinku. / MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. In: Journal of Immunology. 2008 ; Vol. 181, No. 5. pp. 3116-3125.
@article{9e2490d1dc7a468ab6c52aca987438fd,
title = "MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma",
abstract = "MUC1, a membrane tethered mucin glycoprotein, is overexpressed and aberrantly glycosylated in >80{\%} of human ductal pancreatic adenocarcinoma. However, the role of MUC1 in pancreatic cancer has been elusive, partly due to the lack of an appropriate model. We report the characterization of a novel mouse model that expresses human MUC1 as a self molecule (PDA.MUC1 mice). Pancreatic tumors arise in an appropriate MUC1-tolerant background within an immune-competent host. Significant enhancement in the development of pancreatic intraepithelial preneoplastic lesions and progression to adenocarcinoma is observed in PDA.MUC1 mice, possibly due to increased proliferation. Tumors from PDA.MUC1 mice express higher levels of cyclooxygenase-2 and IDO compared with PDA mice lacking MUC1, especially during early stages of tumor development. The increased proinflammatory milieu correlates with an increased percentage of regulatory T cells and myeloid suppressor cells in the pancreatic tumor and tumor draining lymph nodes. Data shows that during pancreatic cancer progression, MUC1-mediated mechanisms enhance the onset and progression of the disease, which in turn regulate the immune responses. Thus, the mouse model is ideally suited for testing novel chemopreventive and therapeutic strategies against pancreatic cancer.",
author = "Tinder, {Teresa L.} and Subramani, {Durai B.} and Basu, {Gargi D.} and Bradley, {Judy M.} and Jorge Schettini and Arefayene Million and Todd Skaar and Pinku Mukherjee",
year = "2008",
month = "9",
day = "1",
language = "English",
volume = "181",
pages = "3116--3125",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma

AU - Tinder, Teresa L.

AU - Subramani, Durai B.

AU - Basu, Gargi D.

AU - Bradley, Judy M.

AU - Schettini, Jorge

AU - Million, Arefayene

AU - Skaar, Todd

AU - Mukherjee, Pinku

PY - 2008/9/1

Y1 - 2008/9/1

N2 - MUC1, a membrane tethered mucin glycoprotein, is overexpressed and aberrantly glycosylated in >80% of human ductal pancreatic adenocarcinoma. However, the role of MUC1 in pancreatic cancer has been elusive, partly due to the lack of an appropriate model. We report the characterization of a novel mouse model that expresses human MUC1 as a self molecule (PDA.MUC1 mice). Pancreatic tumors arise in an appropriate MUC1-tolerant background within an immune-competent host. Significant enhancement in the development of pancreatic intraepithelial preneoplastic lesions and progression to adenocarcinoma is observed in PDA.MUC1 mice, possibly due to increased proliferation. Tumors from PDA.MUC1 mice express higher levels of cyclooxygenase-2 and IDO compared with PDA mice lacking MUC1, especially during early stages of tumor development. The increased proinflammatory milieu correlates with an increased percentage of regulatory T cells and myeloid suppressor cells in the pancreatic tumor and tumor draining lymph nodes. Data shows that during pancreatic cancer progression, MUC1-mediated mechanisms enhance the onset and progression of the disease, which in turn regulate the immune responses. Thus, the mouse model is ideally suited for testing novel chemopreventive and therapeutic strategies against pancreatic cancer.

AB - MUC1, a membrane tethered mucin glycoprotein, is overexpressed and aberrantly glycosylated in >80% of human ductal pancreatic adenocarcinoma. However, the role of MUC1 in pancreatic cancer has been elusive, partly due to the lack of an appropriate model. We report the characterization of a novel mouse model that expresses human MUC1 as a self molecule (PDA.MUC1 mice). Pancreatic tumors arise in an appropriate MUC1-tolerant background within an immune-competent host. Significant enhancement in the development of pancreatic intraepithelial preneoplastic lesions and progression to adenocarcinoma is observed in PDA.MUC1 mice, possibly due to increased proliferation. Tumors from PDA.MUC1 mice express higher levels of cyclooxygenase-2 and IDO compared with PDA mice lacking MUC1, especially during early stages of tumor development. The increased proinflammatory milieu correlates with an increased percentage of regulatory T cells and myeloid suppressor cells in the pancreatic tumor and tumor draining lymph nodes. Data shows that during pancreatic cancer progression, MUC1-mediated mechanisms enhance the onset and progression of the disease, which in turn regulate the immune responses. Thus, the mouse model is ideally suited for testing novel chemopreventive and therapeutic strategies against pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=51549099068&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51549099068&partnerID=8YFLogxK

M3 - Article

C2 - 18713982

AN - SCOPUS:51549099068

VL - 181

SP - 3116

EP - 3125

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -